Trump Policy Reversal Unleashing Billions For Cannabis Industry

In a stunning reversal, powerful conservative politicians are suddenly expressing major support for the cannabis industry.

Most importantly, President Trump has promised to support federal legislation to protect state cannabis laws.

This revolutionary shift in US cannabis policy is creating a huge opportunity for investors.

Here’s a clip from a Bloomberg article with more details:

President Donald Trump endorsed letting states decide how to regulate marijuana, in a major boost for the legal pot industry.

Colorado Republican Senator Cory Gardner said that as a result of Trump’s assurances, he’ll end a blockade of Justice Department nominees. Gardner held up the nominees after Attorney General Jeff Sessions rescinded an earlier Justice Department memo that shielded marijuana operations in states like Colorado from enforcement of the federal ban on the drug.

“Since the campaign, President Trump has consistently supported states’ rights to decide for themselves how best to approach marijuana,” Gardner said in a statement Friday. “President Trump has assured me that he will support a federalism-based legislative solution to fix this states’ rights issue once and for all.”

John Boehner, the former Republican speaker of the House of Representatives, invested and joined the board of one of the largest cannabis companies in the US.

On April 20, New York Senator Chuck Schumer (D-NY) announced plans to introduce a bill that would reschedule the drug classification of cannabis.

These legal game changers could unleash billions in new sales and profits for investors, setting these 7 cannabis stocks soaring. The members of Cannabis Stock Trades have had a nice head start.


#1 – High Hampton Holdings Corp

Ticker: CSE: HC, OTC: HHPHF
Market Cap: $43M
1-Year Return: -39.62%

High Hampton is a young Canadian company that is making big investments in California’s high-growth cannabis market.

For example, on April 18, HC announced that it is buying Caligold – a well-established and recognized edibles brand already generating millions in revenue.

On December 15, HC announced that it had received a favorable environmental site assessment on an 11-acre plot of land in Coachella – where the company has early plans to build a 168K square foot cannabis greenhouse.

I also see a US-based, OTC ticker HHPHF. However, this ticker is not very liquid. Average daily trading volume is just 3,000. With a share price of $0.84, that means just $2,500 in shares are trading hands every day.

I prefer the Canadian ticker – but the US ticker should get the job done too.


#2 – Sunniva, Inc.

Ticker: CSE:SNN, OTC:SNNVF
Market Cap: $176M
1-Year Return: -58.02%

Sunniva is another direct play on California’s high-growth cannabis industry and evolving US cannabis policy.

The company is building a 498,000 square foot cannabis greenhouse in Southern California’s Cathedral City that would be one of the largest in the state.

Construction began in October 2017.

Phase I will be a 325,000-square-feet facility expected to produce 177,000 pounds of dry cannabis annually, with around 50% of production converted into oils and extracts.

Phase II will add 164,000 square feet to the facility, adding 100,000 more pounds of cannabis produced each year.


#3 – Cara Therapeutics

Ticker: NASDAQ: CARA
Market Cap: $781M
1-Year Return: 54.95%

Cara is an up-and-coming cannabis biotech headquartered in the US. Cara has one of the most promising drug pipelines in the cannabis sector – developing cannabis-based drugs to treat pain and pruritus.

Cara’s lead drug candidate, CR485, is in a late-stage study for the treatment of postoperative pain and a treatment of chronic kidney disease-associated pruritus (CKD-aP) which leads to chronic itching for dialysis patients.

This is a promising drug candidate that we’ll want to keep our eye on. I would expect that any good news on CR485 would give shares a nice jolt.


#4 – Innovative Industrial Properties

Ticker: NYSE: IIPR
Market Cap: $291M
1-Year Return: 145.65%

IIPR is headquartered in San Diego and operates in the US.

Shares are traded on the NYSE, making this the only cannabis-related listing on the Big Board.

IIPR owns a real estate portfolio of commercial cannabis greenhouses that it rents to domestic cannabis growers looking to ramp production.

This is a unique cannabis stock. I don’t know of any other company with this business model.

For example, IIPR building a 72,000 square foot greenhouse in Maryland. It just announced a deal to buy a 350,000 square foot greenhouse in Arizona.

Looking forward, IIPR has a robust pipeline of potential investment properties and is expanding its portfolio of commercial cannabis greenhouses.


#5 – Grow Generation, Inc.

Ticker: OTC: GRWG
Market Cap: $120M
1-Year Return: 142.78%

Growgen is a pick-and-shovel play on the US cannabis industry, selling growing supplies and equipment to US cannabis producers.

Growgen has one of the best financial profiles in the US cannabis industry. That means it has strong sales, strong sales growth, and an attractive valuation.

Sales are on pace to come in at around $15 million in 2018. That would be close to a 100% increase from 2016 and an 18% increase from 2017.

With that revenue increase, Growgen looks like one of the most undervalued stocks in the entire cannabis sector. That is important because value stocks are hard to find in the cannabis industry.


#6 – Cannabix Technologies

Ticker: CSE: BLO, OTC: BLOZF
Market Cap: $132M
1-Year Return: 189.36%

Cannabix is an early stage Canadian company that makes a “marijuana breathalyzer.”

Its cannabis breathalyzer product is still in development which means revenue could be months or even years away.

That makes this a higher risk-reward cannabis stock.

Shares are traded on the Canadian Stock Exchange under the ticker symbol BLO. I see average daily trading volume of 1.2 million so that is liquid enough for 99% of regular investors.


#7 – Americann, Inc.

Ticker: OTC: ACAN
Market Cap: $57M
1-Year Return: -3.69%

ACAN is a US cannabis stock that is headquartered in Colorado.

This company hopes to be a supplier for the major markets on the East Coast who have legalized recreational and/or medical cannabis.

In order to achieve that goal, ACAN is in the early stages of building the Massachusetts Medical Cannabis Center (MMMC), which could eventually be a 1 million square foot cannabis greenhouse.

I like the timing of this new greenhouse. Massachusetts is set to go legal in mid-2018 and is expected to quickly grow to a $1.2 billion annual market.


This dramatic shift in cannabis support is creating investment opportunities that only comes once in a lifetime.

While these 7 stocks are in a position to run on Trump support, it takes both time and experience to determine the best time to invest.

To be a successful cannabis investor, you not only have to know WHICH stocks are primed for legitimate success (these are ALWAYS changing), but you have to know WHEN to invest for maximum profits.

While you may not have the time and experience to research the best cannabis stocks and the best times to invest, I do.

I have spent years researching the cannabis industry, identifying stocks ready to break out, and leading my clients and members of Cannabis Stock Trades.

Currently, we have 10 open stock positions with triple-digit returns in our model portfolio. In 2017, our model cannabis portfolio more than doubled in value, gaining 102%.

Replicate returns like this when you join Cannabis Stock Trades today!

  • Get access to a model cannabis portfolio
  • Read hundreds of hours of research and analysis
  • Receive trade alerts and up-to-date industry info
  • Chat with other traders and ask questions

Begin a 2-week free trial to CST today, review our model portfolio, and see where we stand on these 7 Trump pot stocks!

Enjoy,

Michael Vodicka
Editor, Cannabis Stock Trades


Updated August 29, 2018